Description
BimS/EL/L Antibody [3C5] | 36-185 | Gentaur UK, US & Europe Distribution
Host: Rat
Reactivity: Dog, Human, Monkey, Mouse, Rat
Homology: N/A
Immunogen: Synthetic peptide corresponding to aa 20-40 of mouse BimL.
Research Area: Apoptosis, Cancer
Tested Application: E, Flow, ICC, IHC, IP, WB
Application: ChIP: (1:200) Band shift assay: Competes with probe for NFAT binding. . Immunoprecipitation: (1:200) . Western Blot: (1:500-1:1000) . Optimal conditions must be determined individually for each application.
Specificiy: Recognizes an epitope within aa 20-40 of human, mouse, rat, monkey and dog BimL (~19kDa) , BimEL (~23kDa) , and BimS (~16kDa) . Also recognizes the six novel isoforms of human Bim, generated by alternative splicing and lacking the C-terminal hydrophobic region.
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: >95% (SDS-PAGE)
Clonality: Monoclonal
Clone: 3C5
Isotype: IgG2a, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Liquid. In PBS containing 0.02% sodium azide and 25% glycerol.
Concentration: 1 mg/ml
Storage Condition: Stable for at least 1 year after receipt when stored at -20˚C.
Alternate Name: BCL2L11; Bcl-2-like Protein 11; Bcl2-interacting Mediator of Cell Death
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Bim belongs to the Bcl-2 protein family. Bcl-2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. This protein contains a Bcl-2 homology domain 3 (BH3) . It has been shown to interact with other members of the Bcl-2 protein family (BCL2, BCL2L1/BCL-X (L) and MCL1) and to act as an apoptotic activator, inducing apoptosis and anoikis. Several variants have been identified. The isoforms vary in cytotoxicity with isoform BimS being the most potent and isoform BimEL being the least potent.